Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
- no estimate extracted2 studies · 1065 participantsHigh